WallStSmart

Healthpeak Properties Inc (DOC)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 12% more annual revenue ($3.22B vs $2.87B). WST leads profitability with a 16.9% profit margin vs 7.7%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 67/100 (B-).

DOC

Buy

54

out of 100

Grade: C-

Growth: 8.0Profit: 4.5Value: 4.7Quality: 3.5
Piotroski: 2/9Altman Z: 0.24

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOCUndervalued (+46.2%)

Margin of Safety

+46.2%

Fair Value

$31.53

Current Price

$19.64

$11.89 discount

UndervaluedFair: $31.53Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DOC2 strengths · Avg: 9.0/10
EPS GrowthGrowth
363.9%10/10

Earnings expanding 363.9% YoY

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

DOC4 concerns · Avg: 3.0/10
Return on EquityProfitability
2.8%3/10

ROE of 2.8% — below average capital efficiency

Profit MarginProfitability
7.7%3/10

7.7% margin — thin

Debt/EquityHealth
1.393/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DOC

The strongest argument for DOC centers on EPS Growth, Price/Book.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : DOC

The primary concerns for DOC are Return on Equity, Profit Margin, Debt/Equity. A P/E of 61.4x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

DOC profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

DOC generates stronger free cash flow (261M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 54/100), backed by strong 16.9% margins and 21.0% revenue growth. DOC offers better value entry with a 46.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthpeak Properties Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Physicians Realty Trust is a self-managed healthcare real estate company organized to acquire, selectively develop, own and manage healthcare properties that are rented to physicians, hospitals and healthcare delivery systems.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?